December 11, 2024 | ESG, Sustainability
Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of companies assessed and within the 97th percentile, a testament to their unwavering commitment to sustainability and advanced ESG practices.

Following the assessment of the 2024 EcoVadis submission, Cuttsy+Cuttsy is excited to announce they have been awarded a Gold Medal on their sustainability scorecard. This places the agency among the top 5% of companies assessed by EcoVadis in the past 12 months.
Not only this, but Cuttsy+Cuttsy’s high score placed them in the 97th percentile of all companies assessed in 2024, making them just shy of a platinum rating (the top possible rating within the EcoVadis scoring system).
EcoVadis, a globally trusted provider of business sustainability ratings with a network of over 130,000 rated companies, works with organisations of all sizes to measure sustainability performance. The platform offers detailed insights on environmental, social and governance (ESG) risk management, compliance and corporate sustainability goals.
Caroline Benson, Co-Founder, says, “We’re delighted with our ‘gold’ rating, a big advancement from last year’s ‘silver’, that showcases our dedication to continuous improvement across all our ESG practices.”
Mathew Cutts adds, “This achievement reinforces our pledge to uphold and exceed the highest standards in sustainability across our operations and value chain.”
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
